Search Results - "Soon, Rachel"
-
1
Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study
Published in Clinical infectious diseases (05-10-2021)“…KAF156 is a novel antimalarial drug that is active against both liver- and blood-stage Plasmodium parasites, including drug-resistant strains. Here, we…”
Get full text
Journal Article -
2
The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model
Published in Antimicrobial Agents and Chemotherapy (01-10-2012)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
3
Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies
Published in Journal of antimicrobial chemotherapy (01-11-2016)“…Polymyxin B is being increasingly utilized as a last resort against resistant Gram-negative bacteria. We examined the pharmacodynamics of novel dosing…”
Get full text
Journal Article -
4
Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment
Published in Journal of antimicrobial chemotherapy (01-01-2011)“…electrostatic forces mediate the initial interaction between cationic colistin and Gram-negative bacterial cells. Lipopolysaccharide (LPS) loss mediates…”
Get full text
Journal Article -
5
Atomic Force Microscopy Investigation of the Morphology and Topography of Colistin-Heteroresistant Acinetobacter baumannii Strains as a Function of Growth Phase and in Response to Colistin Treatment
Published in Antimicrobial Agents and Chemotherapy (01-12-2009)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
6
-
7
Design, synthesis, and evaluation of a new fluorescent probe for measuring polymyxin–lipopolysaccharide binding interactions
Published in Analytical biochemistry (15-02-2011)“…Fluorescence assays employing semisynthetic or commercial dansyl-polymyxin B have been widely employed to assess the affinity of polycations, including…”
Get full text
Journal Article -
8
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations
Published in Antimicrobial agents and chemotherapy (01-04-2016)“…Despite a dearth of new agents currently being developed to combat multidrug-resistant Gram-negative pathogens, the combination of ceftolozane and tazobactam…”
Get full text
Journal Article -
9
The DGAT1 inhibitor pradigastat does not induce photosensitivity in healthy human subjects: a randomized controlled trial using three defined sunlight exposure conditions
Published in Photochemical & photobiological sciences (01-01-2016)“…The DGAT1 inhibitor, pradigastat, demonstrated a mild phototoxicity signal in preclinical studies. Therefore, this clinical trial was conducted to assess the…”
Get more information
Journal Article -
10
Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus
Published in International journal of antimicrobial agents (01-07-2013)“…Abstract Daptomycin is a novel lipopeptide exhibiting concentration-dependent bactericidal activity against multidrug-resistant Gram-positive pathogens,…”
Get full text
Journal Article -
11
In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing escherichia coli in a hollow-fibre infection model
Published in International journal of antimicrobial agents (01-01-2017)“…Highlights • Ceftolozane/tazobactam is highly active against certain Escherichia coli strains. • Diminished activity was observed against a CTX-M-15-producing…”
Get full text
Journal Article -
12
Pharmacodynamic Variability beyond That Explained by MICs
Published in Antimicrobial Agents and Chemotherapy (01-04-2013)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
13
Effect of colistin exposure and growth phase on the surface properties of live Acinetobacter baumannii cells examined by atomic force microscopy
Published in International journal of antimicrobial agents (01-12-2011)“…Abstract The diminishing antimicrobial development pipeline has forced the revival of colistin as a last line of defence against infections caused by…”
Get full text
Journal Article -
14
Molecular basis for the increased polymyxin susceptibility of Klebsiella pneumoniae strains with under-acylated lipid A
Published in Innate immunity (London, England) (01-06-2013)“…The impact of under-acylation of lipid A on the interaction between Klebsiella pneumoniae LPS and polymyxins B and E was examined with fluorometric and…”
Get more information
Journal Article -
15
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
Published in Clinical pharmacology and therapeutics (01-12-2019)“…This open‐label disease‐drug–drug interaction study assessed whether blockade of the interleukin (IL)‐17A pathway by secukinumab and subsequent downregulation…”
Get full text
Journal Article -
16
Preliminary Comparison of Major Adverse Outcomes in Patients With Nonalcoholic Fatty Liver Disease Initiated on Second-Line Antihyperglycemic Therapy
Published 01-01-2023“…Objectives: To assess long-term hepatic and cardiovascular outcomes in patients with both nonalcoholic fatty liver disease (NAFLD) and type II diabetes who are…”
Get full text
Dissertation -
17
GS07 - Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing
Published in Journal of hepatology (01-08-2020)Get full text
Journal Article -
18
Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing
Published in Journal of hepatology (01-08-2020)Get full text
Journal Article -
19
-
20
Proposing a Foundational IoT Smart Planter Concept towards Reducing Carbon Footprint in Malaysia via Gamification
Published in 2022 International Conference on Computer and Drone Applications (IConDA) (28-11-2022)“…The rise in the concentration of greenhouse gases, predominantly carbon dioxide (CO 2 ), has contributed to the rising rate of climate change and global…”
Get full text
Conference Proceeding